详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking Univ Canc Hosp, Dept Lymphoma, Beijing, Peoples R China [2]Peking Univ Int Hosp, Dept Lymphoma, Beijing, Peoples R China [3]Lanzhou Univ Second Hosp, Lanzhou, Peoples R China [4]Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China [5]China Japan Friendship Hosp, Beijing, Peoples R China [6]Hebei Med Univ, Hosp 4, Hebei Tumor Hosp, Dept Hematol, Shijiazhuang, Peoples R China [7]Inner Mongolia Med Univ, Afliated Hosp, Hohhot, Peoples R China [8]Chifeng Municipal Hosp, Dept Hematol, Chifeng, Peoples R China [9]Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China [10]Guangdong Hosp Tradit Chinese Med, Guangzhou, Peoples R China [11]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Beijing, Peoples R China [12]Peking Univ Canc Hosp, Beijing, Peoples R China

出处：

DOI：

ISSN：

关键词： Lymphoma Extranodal NK-T-Cell Immunotherapy Therapeutics Prognosis

语种：

WOS：

中科院分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 HEMATOLOGY

影响因子： 21.1 最新[2023版] 19.2 最新五年平均 21.1 出版当年[2024版] 19.2 出版当年五年平均 21.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Peking Univ Canc Hosp, Dept Lymphoma, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group. [2]Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group. [3]Evidence of Cure for Extranodal Nasal-Type NK/T-Cell Lymphoma with Modern Treatment [4]Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma [5]The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma [6]Solitary Epstein-Barr virus-positive cytotoxic T cell lymphoproliferative disease in stomach mimicking extranodal NK/T cell lymphoma [7]Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma [8]结外鼻型NK/T细胞淋巴瘤ⅡB继发噬血细胞综合征一例 [9]First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. [10]99例结外NK/T细胞淋巴瘤预后分析